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Abstract
Background: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for
allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the
first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome.
However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events
following RIC due to the relative recent introduction of this approach.
Methods: We analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥50 years, after SCT from
HLA-matched siblings, during the years 1997–2005, median follow-up 8.3 years (0.1–17).
Results: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27–35) and 32 % (28–35) after MAC and RIC,
respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18–25)
and 21 % (18–24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was
lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving
leukemia-free 2 years after SCT was 71 % (65–76) and 73 % (67–78) after MAC and RIC, respectively (P = 0.76). Advanced
leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of
late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers
were more common causes of late death after MAC.
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Conclusions: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the
first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome
after both approaches.
Keywords: Acute myeloid leukemia, Allogeneic stem cell transplantation, Myeloablative conditioning, Reduced-intensity
conditioning, Long-term outcome
Background
Allogeneic hematopoietic stem cell transplantation
(SCT) is a potentially curative approach in patients with
acute myeloid leukemia (AML). Substantial improvement
has been achieved in the last decades in SCT outcomes
owing to improved supportive care and transplantation
techniques and a larger proportion of SCT recipients are
becoming long-term survivors [1].
Reduced-intensity conditioning (RIC) has been widely
introduced over the past 15 years to allow SCT in elderly
and medically infirm patients not eligible for standard
myeloablative conditioning (MAC) [2]. Several studies have
shown similar survival of AML patients after SCT with RIC
or MAC [3–9]. Most of these studies have shown that RIC
is associated with reduced non-relapse mortality (NRM)
but increased relapse rate, resulting in a similar leukemia-
free survival (LFS) as MAC. However, due to the more
recent introduction of RIC, there is paucity of data on the
long-term outcome (beyond 10 years) after RIC.
Most deaths after SCT occur within the first 2 years
[10]. Long-term survivors remain at increased risk for late
complications and late morbidity and mortality that is
higher than their sibling donors or the age- and gender-
matched general population [11–13]. In the largest study
of long-term survivors, the Center of International Blood
and Marrow Transplantation Research (CIBMTR) has
shown that the probability of patients who were alive and
disease-free at 2 years after SCT to remain alive 10 years
after SCT was 85 % (84 % among patients with AML)
[13]. Relapse was the most common cause of late death,
but chronic graft-versus-host disease (GVHD), infections,
organ toxicity and second cancers were also important
causes of late mortality. These observations were limited
to MAC recipients, and there is, similarly, paucity of data
on the kinetics of late events after RIC and the expected
outcomes of 2-year survivors after RIC.
In this study, we show that 10-year survival is similar
after RIC and MAC, and that 2-year survivors after RIC
can expect a similarly favorable outcome as 2-year survivors
after MAC.
Methods
Study design and data collection
This is a retrospective multicenter analysis. Data were pro-
vided and approved for this study by the acute leukemia
working party (ALWP) of the European Group for Blood
and Marrow Transplantation (EBMT). Eligibility criteria
included age ≥50 years, de novo AML in any disease
status at SCT, transplants from HLA-compatible sibling
donors between 1997 and 2005 with bone marrow (BM) or
granulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (PBSC) after MAC or RIC. Pa-
tients given unrelated or alternative donor grafts were not
included. Variables collected included recipient and donor
characteristics, disease features, transplant related factors
including drugs and total doses used in the conditioning
regimen, and outcome variables.
Conditioning regimens
The conditioning regimen was selected according to the
participating center discretion. Dose intensity was defined
according to EBMT criteria based on the reversibility and
expected duration of cytopenia after SCT [3]. MAC
consisted of high-dose cyclophosphamide and high-dose
busulfan (BuCy) or total body irradiation (TBI). Reduced-
toxicity myeloablative regimens consisted of a com-
bination of fludarabine and myeloablative dose of an
alkylating agent (such as intravenous busulfan at a total
dose ≥9.6 mg/kg, melphalan >140 mg/m2, treosulfan ≥ 36
g/m2) were included with MAC. RIC consisted of fludara-
bine combined with reduced dose alkylating agent (such
as busulfan < 9.6 mg/kg) or low-dose TBI (<8 Gy). GVHD
prophylaxis consisted of cyclosporine A and a short
course of methotrexate in most patients. In vivo T cell
depletion with anti-thymocyte globulin (ATG) or alemtu-
zumab was allowed according to the participating center
policy.
Evaluation of outcomes
Disease relapse was defined according to standard
hematological criteria. NRM was defined as death of any
cause in the absence of prior disease recurrence. LFS
was defined as survival without relapse. Overall survival
(OS) was calculated from the day of SCT until death of
any cause or last follow-up. GVHD-free relapse-free
survival (GRFS) was defined by the first of the following
event: acute GVHD grades III-IV, extensive chronic
GVHD, relapse or death [14]. Patients with no event
were censored at last contact. The cause of death was
categorized according to standard criteria. The cause of
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death of patients who experienced relapsed disease at
any time prior to death was considered relapse-related.
Death in patients with active GVHD was defined as
GVHD-related even if directly related to other cause.
Statistical analysis
The primary end point of the study was 10-year LFS. Sec-
ondary endpoints included NRM, relapse incidence (RI),
OS, acute and chronic GVHD, and GRFS. Cumulative inci-
dence functions (CIF) were used to estimate RI and NRM
in a competing risks setting, with death and relapse consid-
ered as competing events with each other [15]. In the ana-
lysis of chronic GVHD, relapse and death were considered
to be competing events. The probabilities of LFS, OS, and
GRFS were calculated using the Kaplan–Meier estimates.
The two regimen intensity groups were compared by the
chi-square method for qualitative variables, and Mann–
Whitney test for continuous parameters. Log-rank test was
used for examining the difference in survivor curves for
LFS, OS, and GRFS. Gray test was uses to analyze the
difference in cumulative incidence curves for RI and NRM.
The variables considered were patient age at transplant-
ation, recipient gender, female donor to male recipient,
cytogenetics risk group, status at transplantation (CR1,
CR2/3 and active disease), source of stem cells (PB vs. BM),
donor/recipient CMV seropositivity, in vivo T cell deple-
tion, and year of transplantation. Multivariable analyses
were performed using Cox proportional hazards model for
LFS and Fine-Gray model for RI and NRM [16]. For all
prognostic analyses, continuous variables were categorized
and the median used as a cut-off point. All interactions
between conditioning and other variables were studied.
Landmark analysis was performed in order to evaluate the
impact of prognostic variables on the outcome of patients
alive and with no relapse at 2 years after SCT [17]. Prognos-
tic factors for assessment of outcomes subsequent to the
landmark time-point were assessed using similar methods.
Statistical analyses were performed with SPSS 19.0 (Inc.,
Chicago) and R2.14.2 software packages (R Development
Core Team, Vienna, Austria).
Results
Patient characteristics
Patient, disease and transplant characteristics are outline
in Table 1. A total of 1423 patients were included in the
analysis; 701 patients had MAC and 722 had RIC, re-
spectively. The median age at SCT was 54 years (50–72)
and 57 years (range, 50–75), respectively (P < 0.0001).
Twenty-five percent of MAC recipients had advanced
disease at SCT compared with 21 % of RIC recipients.
The percentage of patients in CR1 and CR2/ later CR
was 63 and 12 % after MAC and 62 and 17 % after RIC,
respectively (P = 0.01). In vivo T cell depletion included
ATG (either Fresenius at a total dose of 15–60 mg/kg or
thymoglobulin at 2.5–10 mg/kg) or alemtuzumab. RIC
recipients were more likely to receive PBSC rather than
BM (92 vs. 73 %, P < 0.0001) and in vivo T cell depletion
(33 vs. 12 %, P < 0.0001). Twenty percent of MAC
recipients and 16 % of RIC recipients had poor-risk
cytogenetics, respectively (P = 0.19). The median year of
transplant for patients in the MAC group was 2002
(range, 1997–2005) while patients in the RIC group were
transplanted more recently, median year 2003 (range,
1997–2005, P < 0.0001). The median follow-up was
8.7 years (range, 0.1–17.0) and 8.1 years (range, 0.1–14.9),
respectively.
Non-relapse mortality and chronic GVHD
The 10-year NRM was 35 % (95 % CI, 31–39) and 20 %
(95 % CI, 17–24) after MAC and RIC, respectively
(P < 0.0001). Multivariate analysis identified RIC (hazard
ratio (HR) 0.56, P < 0.00001), age >55 years (HR 1.5,
P = 0.004), advanced disease (HR 1.6, P = 0.02), and
transplantation from female donor to male recipient
(HR 1.4, P = 0.01) as factors predicting NRM (Table 2).
Chronic GVHD occurred in 40 and 43 %, respectively
(P = 0.19). The factors predicting for chronic GVHD
that may govern quality of life after SCT were in vivo
Table 1 Patient characteristics
MAC
(n = 701)
RIC
(n = 722)
P value
Age (median, years) 54 (50–72) 57 (50–75) <0.0001
Gender (male) 381 (54 %) 395 (55 %) 0.89
F→M 157 (23 %) 193 (27 %) 0.05
Cytogenetics
Good 31 (8 %) 43 (8 %) 0.19
Intermediate 316 (77 %) 393 (72 %)
Poor 66 (16 %) 112 (20 %)
Missing 288 174
Status at SCT
CR1 443 (63 %) 450 (62 %) 0.01
CR2 84 (12 %) 122 (17 %)
Advanced 174 (25 %) 150 (21 %)
Stem cell source
(PBSC)
515 (73 %) 665 (92 %) <0.0001
In vivo T cell depletion 81 (12 %) 239 (33 %) <0.0001
ATG 55 (8 %) 172 (24 %)
Alemtuzumab 26 (4 %) 67 (9 %)
Patient CMV + 336 (66 %) 452 (73 %) 0.02
Donor CMV + 284 (58 %) 398 (65 %) 0.009
Year of SCT
(median, range)
2002 (1997–2005) 2003 (1997–2005) <0.0001
Abbreviations: MAC myeloablative conditioning, RIC reduced-intensity conditioning,
F→M female donor to male recipient, SCT stem cell transplantation, PBSC
peripheral blood stem cell, ATG anti-thymocyte globulin
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T cell depletion (HR 0.62, P = 0.0002), advanced dis-
ease (HR 1.4, P = 0.01), and PBSC transplantation (HR
1.45, P = 0.01) but not the conditioning regimen used.
Relapse
The 10-year relapse incidence was 34 % (95 % CI, 31–38)
and 48 % (95 % CI, 44–52) after MAC and RIC, respect-
ively (P < 0.0001). However, after adjusting for multiple
variables RIC was no longer associated with increased
relapse risk (HR 1.2, P = 0.13, Table 2). Relapse was
predicted by SCT at CR2/later CR (HR 1.7, P = 0.0004)
or advanced disease (HR 2.7, P < 0.00001), in vivo T
cell depletion (HR 1.4, P = 0.01), age >55 years (HR 1.5,
P = 0.0004), and poor cytogenetics (HR 3.4, P = 0.0002)
(Table 2).
LFS, OS, and GRFS
The 10-year LFS was 31 % (95 % CI, 27–35) and 32 %
(95 % CI, 28–35) after MAC and RIC, respectively
(P = 0.57). LFS was similar after MAC and RIC in patients
age 50–55 years, been 36 % (95 % CI, 32–41) and 40 %
(95 % CI, 33–46), respectively (P = 0.32). However, there
was an advantage for RIC in patients age >55 years, 28 %
(95 % CI, 24–32) and 20 % (95 % CI, 14–26), respectively
(Fig. 1, P = 0.02). RIC was also associated with an
advantage in LFS in patients with good risk cytogenetics,
but LFS was similar in the different subsets according to
disease status at SCT. In all, multivariable analysis
identified SCT at CR2/later CR (HR 1.5, P = 0.0001) or
advanced disease (HR 2.2, P < 0.00001), age >55 years
(HR 1.4, P < 0.00001), and poor cytogenetics (HR 1.7,
P = 0.005) as factors predicting for LFS (Table 3).
The 10-year OS was 33 % (95 % CI, 29–37) and
35 % (95 % CI, 32–39) after MAC and RIC, respect-
ively (P = 0.57). Multivariable analysis identified SCT at
CR2/later CR (HR 1.6, P = 0.0004) or advanced disease
(HR 2.2, P < 0.00001), age >55 years (HR 1.5, P < 0.00001)
and poor cytogenetics (HR 1.5, P = 0.04) as factors associ-
ated with reduced OS. RIC was associated with a better
10-year OS (HR 0.8, P = 0.01).
The 10-year GRFS, a surrogate for quality of life was
22 % (18–25) and 21 % (18–24), after MAC and RIC, re-
spectively (P = 0.79). Multivariable analysis identified
SCT at CR2/later CR (HR 1.4, P = 0.0008) or advanced
Table 2 Multivariate analysis of pre-transplant factors predicting for NRM, relapse, and chronic GVHD
NRM Relapse Chronic GVHD
Factor HR
(95 % CI)
P value HR
(95 % CI)
P value HR
(95 % CI)
P value
RIC vs. MAC 0.56
(0.43–0.74)
0.0004 1.19
(0.95–1.49)
0.13 1.19
(0.95–1.49)
0.12
CR2 vs. CR1 1.35
(0.96–1.90)
0.09 1.68
(1.26–2.23)
0.0004 1.10
(0.82–1.46)
0.53
Advanced vs. CR1 1.61
(1.19–2.17)
0.002 2.71
(2.17–3.38)
<0.00001 1.42
(1.08–1.85)
0.01
In vivo T cell depletion 0.85
(0.62–1.17)
0.33 1.35
(1.09–1.68)
0.01 0.62
(0.49–0.80)
0.0002
Age > 55 years 1.46
(1.13–1.89)
0.004 1.45
(1.13–1.89)
0.0004 1.00
(0.82–1.23)
0.99
F→M 1.41
(1.09–1.83)
0.01 1.03
(0.83–1.28)
0.78 1.11
(0.89–1.38)
0.37
Cytogenetics
Intermediate vs. good 0.73
(0.46–1.16)
0.18 1.70
(1.01–2.86)
0.05 0.76
(0.53–1.11)
0.16
Poor vs. good 0.63
(0.35–1.13)
0.12 3.36
(1.94–5.84)
0.0002 0.71
(0.45–1.11)
0.13
Missing 0.77
(0.46–1.27)
0.31 1.67
(0.96–2.91)
0.07 0.78
(0.51–1.21)
0.27
Year of SCT 0.96
(0.91–1.01)
0.12 0.98
(0.93–1.02)
0.30 1.01
(0.97–1.06)
0.58
Patient CMV + 1.22
(0.92–1.61)
0.17 0.94
(0.75–1.17)
0.56 0.99
(0.80–1.23)
0.95
Donor CMV + 0.88
(0.68–1.14)
0.33 1.03
(0.84–1.27)
0.79 0.98
(0.80–1.21)
0.87
PBSC vs. BM 0.90
(0.66–1.24)
0.53 0.80
(0.61–1.05)
0.10 1.45
(1.08–1.95)
0.01
Abbreviations: as in Table 1. NRM non-relapse mortality, BM bone marrow
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disease (HR 2.0 P < 0.00001), age >55 years (HR 1.3,
P = 0.002) and poor cytogenetics (HR 1.6, P = 0.01) as
factors associated with reduced GRFS. In vivo T cell
depletion was associated with improved GRFS (HR
0.8, P = 0.04). RIC and MAC were associated with
similar GRFS (Table 3). There was no difference in LFS,
OS or GRFS according to the agent used for in vivo T cell
depletion (ATG or alemtuzumab). In the global popula-
tion there was a lower incidence of acute GVHD after
alemtuzumab compared to ATG, but there was no differ-
ence in the incidence of chronic GVHD or NRM.
Landmark analysis
Five hundred and eighty-four patients were alive and
leukemia-free 2 years after SCT, 287 after MAC and 297
after RIC. The 10-year LFS of patients surviving leukemia-
free at the 2-year landmark was 71 % (65–76) and 73 %
(67–78), respectively (Fig. 2a, global P = 0.76). Multivariate
analysis identified advanced disease at SCT (HR 1.9,
P = 0.01) and female donor to male recipient (HR 1.5,
P = 0.04) as independent factors predicting LFS. The
conditioning regimen, age, cytogenetics and prior
chronic GVHD were not significant (Table 4). The
10-year overall survival (OS) was 73 % (67–78) and
74 % (69–80), respectively (Fig. 2b, global P = 0.81).
Advanced disease was the only predicting factor in
multivariate analysis (HR 2.0, P = 0.01).
Table 5 outlines the causes of late deaths by the
regimen and time after SCT. There were 86 late deaths
after MAC, 53 of them 2–5 years after SCT and 33
beyond 5 years. Ninety-seven deaths occurred after RIC,
67 of them 2–5 years after SCT and 30 beyond 5 years.
Relapse was the leading cause of late death after both
regimens. It was the cause of 72 and 87 % of deaths 2–5
years after MAC and RIC, respectively (P = 0.06), and
42 and 83 % of deaths beyond 5 years, respectively
(P = 0.006). In all, the 10-year relapse rate was 14 %
(10–19) and 19 % (14–24), respectively (Fig. 3a, P = 0.12).
Multivariate analysis identified disease status at SCT
(P = 0.02) and poor cytogenetics (P = 0.04) as factors
predicting for late relapse. The regimen used was not pre-
dictive. Prior chronic GVHD was no longer protective
against relapse in patients reaching the 2-year landmark
leukemia-free. NRM was the cause of 28 and 13 % of
deaths 2–5 years after MAC and RIC, and 58 and 17 % of
deaths beyond 5 years, respectively. In particular, GVHD
was the cause of 14 and 6 % of late deaths after
MAC and RIC (P = 0.08) while second cancers were
the cause of 12 and 2 %, respectively (P = 0.01). In all,
the 10-year late NRM rate was 15 % (11–20) and 9 %
(6–13), respectively (Fig. 3b, P = 0.03). Multivariate
analysis identified RIC (HR 0.4, P = 0.006), advanced
disease at SCT (HR 2.3, P = 0.03), age >55 years (HR
1.8, P = 0.07), and chronic GVHD (HR 2.0, P = 0.03)
as factors predicting for late NRM.
In patients surviving leukemia-free 5 years after SCT,
the subsequent NRM was 9 and 4 % after MAC and
RIC, respectively (P = 0.06). Subsequent relapse rate
were 5 and 6 % (P = 0.53), and LFS was 86 and 90 %,
respectively (P = 0.27).
Discussion
The current study shows that with long-term follow-up
LFS is similar after allogeneic SCT from HLA- matched
siblings with RIC and MAC in patients with AML
age >50 years. The role of dose intensity in SCT con-
ditioning for AML has been explored in multiple
retrospective studies [18] (reviewed in 18). Most stud-
ies have shown that more intensive regimens control
leukemia better, but LFS is not improved due to
Fig. 1 Overall survival after allogeneic stem cell transplantation in patients age 50–55 years (a) or >55 years (b)
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Fig. 2 Subsequent outcomes of patients who were leukemia-free 2 years after stem cell transplantation. Overall survival (a). Leukemia-free
survival (b)
Table 3 Multivariate analysis of pre-transplant factors predicting for LFS, OS, and GRFS
LFS OS GRFS
Factor HR
(95 % CI)
P value HR
(95 % CI)
P value HR
(95 % CI)
P value
RIC vs. MAC 0.88
(0.74–1.05)
0.15 0.78
(0.65–0.93)
0.01 1.03
(0.87–1.20)
0.75
CR2 vs. CR1 1.53
(1.23–1.91)
0.0001 1.59
(1.27–2.00)
0.00004 1.42
(1.16–1.74)
0.0008
Advanced vs. CR1 2.22
(1.86–2.66)
<0.00001 2.24
(1.87–2.68)
<0.00001 1.95
(1.64–2.31)
<0.00001
In vivo T cell depletion 1.16
(0.97–1.39)
0.10 1.10
(0.92–1.32)
0.31 0.84
(0.71–0.99)
0.04
Age >55 years 1.44
(1.22–1.69)
<0.00001 1.52
(1.29–1.80)
<0.00001 1.27
(1.09–1.47)
0.002
F→M 1.17
(0.99–1.38)
0.06 1.18
(0.99–1.40)
0.06 1.14
(0.97–1.33)
0.10
Cytogenetics
Intermediate vs. good 1.12
(0.79–1.57)
0.53 1.10
(0.77–1.56)
0.59 1.08
(0.79–1.47)
0.63
Poor vs good 1.72
(1.18–2.50)
0.005 1.51
(1.03–2.23)
0.04 1.58
(1.12–2.24)
0.01
Missing 1.12
(0.77–1.62)
0.56 1.06
(0.72–1.55)
0.77 1.24
(0.88–1.74)
0.22
Year of SCT 0.97
(0.94–1.00)
0.06 0.96
(0.93–1.00)
0.03 0.97
(0.94–1.00)
0.08
Patient CMV + 1.05
(0.88–1.25)
0.58 1.09
(0.92–1.31)
0.32 0.98
(0.83–1.15)
0.77
Donor CMV + 0.96
(0.81–1.13)
0.59 0.93
(0.79–1.10)
0.41 0.99
(0.85–1.15)
0.90
PBSC vs. BM 0.84
(0.69–1.03)
0.10 0.87
(0.70–1.07)
0.18 1.05
(0.86–1.27)
0.64
Abbreviations: as in Tables 1 and 2. LFS leukemia-free survival, OS overall survival, GRFS GVHD-free relapse-free survival
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excess NRM. In a prior report the ALWP of EBMT
has shown in a comparison of 315 RIC and 407
MAC recipients, age >50 years, that NRM was lower with
RIC, relapse was higher, resulting in similar 2-year LFS
[3]. The current analysis includes the same group, ex-
tended with data accumulating from more patients, trans-
planted during the same period, now followed for almost
10 years. It shows that these shorter-term observations
remained with long-term follow-up. The 10-year LFS was
31 % (95 % CI, 27–35) and 32 % (95 % CI, 28–35) after
MAC and RIC, respectively (P = 0.57). In addition, the
GRFS, which is a surrogate for quality of life analysis, was
similar between the two regimens. Several retrospective
analyses and meta-analyses supported these observations
[4–9]. Luger et al. reported in the largest such comparison
from CIBMTR, including 3731 MAC and 1448 RIC/
Table 4 Multivariate analysis of factors predicting for transplantation outcomes in patients surviving leukemia-free 2 years after
transplantation
NRM Relapse LFS
Factor HR
(95 % CI)
P value HR
(95 % CI)
P value HR
(95 % CI)
P value
RIC vs. MAC 0.36
(0.18–0.75)
0.006 1.14
(0.64–2.03)
0.65 0.77
(0.49–1.19)
0.24
CR2 vs. CR1 0.55
(0.18–1.65)
0.29 2.44
(1.28–4.68)
0.007 1.55
(0.89–2.70)
0.12
Advanced vs. CR1 2.28
(1.07–4.85)
0.03 1.68
(0.82–3.44)
0.16 1.91
(1.14–3.21)
0.01
In vivo T cell depletion 1.34
(0.60–2.99)
0.47 1.06
(0.60–1.88)
0.83 1.17
(0.74–1.86)
0.49
Age >55 years 1.82
(0.96–3.48)
0.07 1.21
(0.73–2.02)
0.46 1.37
(0.92–2.04)
0.12
F→M 1.72
(0.92–3.22)
0.09 1.46
(0.85–2.51)
0.17 1.53
(1.02–2.29)
0.04
Cytogenetics
Intermediate vs. good 0.35
(0.12–0.97)
0.04 8.09
(1.08–60.79)
0.04 1.43
(0.62–3.30)
0.40
Poor vs. good 0.18
(0.04–0.82)
0.03 9.82
(1.16–82.79)
0.04 1.29
(0.47–3.56)
0.63
Missing 0.34
(0.10–1.13)
0.08 5.54
(0.69–44.58)
0.11 1.14
(0.45–2.87)
0.79
Year of SCT 1.01
(0.87–1.17)
0.90 1.03
(0.91–1.16)
0.62 1.02
(0.93–1.12)
0.67
Patient CMV + 1.19
(0.61–2.35)
0.61 0.86
(0.51–1.47)
0.59 0.98
(0.65–1.47)
0.90
Donor CMV + 1.27
(0.65–2.47)
0.49 0.74
(0.45–1.23)
0.25 0.89
(0.60–1.32)
0.56
PBSC vs. BM 0.80
(0.37–1.76)
0.59 1.11
(0.54–2.32)
0.77 0.94
(0.55–1.59)
0.81
Chronic GVHD before 2 years 2.04
(1.06–3.92)
0.03 0.84
(0.52–1.38)
0.50 1.15
(0.78–1.70)
0.47
Abbreviations: as in Tables 1, 2 and 3
Table 5 Causes of late death by conditioning regimen and time after transplantation
MAC RIC
2–5 years 5–10 years >10 years 2–5 years 5–10 years >10 years
Infection 2 4 0 2 1 0
GVHD 8 3 1 4 1 1
Second malignancy 1 4 5 1 1 1
Other NRM 4 1 1 2 0 0
Relapse 38 14 0 58 23 2
Abbreviations: as in Tables 1, 2, 3, and 4. Early causes of death (before 2 years) are not listed
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nonmyeloablative (NMA) recipients, that the 5-year OS
rates were 34, 33, and 26 % after MAC, RIC, and NMA
conditioning, respectively [5]. OS was similar after RIC
and MAC but inferior after NMA. However, in this study
NRM was lower after RIC only in the early post SCT
period. By 3 years, late NRM negated this early advantage
and NRM rates became equivalent. In the current analysis,
NRM rate was lower after RIC throughout the post-
transplant course up to 10 years after SCT. This is pos-
sibly explained by the selection of patient age ≥50 years in
this analysis, compared to all adult patients in the
CIBMTR study. Thus, the median age of MAC recipients
was 54 and 42 years in the different studies respectively,
while the median age of RIC recipients was similar. Older
MAC recipients may be more prone to NRM in the late
post SCT period than younger recipients. Advanced age is
a predictor of NRM in many of these studies. Historically,
only younger patients (<35–40) benefited from SCT with
MAC in CR1 compared with chemotherapy, due to
excess NRM [19]. However, RIC has extended the
benefit to older patients [20, 21]. In the current ana-
lysis, RIC was associated with better long-term LFS
than MAC in patients age >55 years.
However, all these analyses may be associated with a
selection bias. Several randomized comparisons have
been reported over the last years. Bornhauser et al. ran-
domized patients with AML in CR1 to standard MAC
(with 12Gy TBI) or RIC with an intermediate dose of
TBI (total 8Gy) [22]. The 3-year LFS was similar among
the regimens. The GITTMO group randomized patients
to BuCy versus fludarabine and high-dose busulfan
(FB4) [23]. NRM was reduced with the FB4 regimen but
LFS was similar. It should be noted that the RIC arms in
both these studies would be considered MAC according
to the registry criteria used in the current analysis. These
regimens are better defined as reduced-toxicity myeloa-
blative regimens (RTC). Scott et al. randomized patients
to conventional RIC versus MAC [24]. The study was
stopped early as relapse rates were markedly higher in
the RIC group. The reduction in NRM was not sufficient
to compensate for this elevated risk and LFS was higher
after MAC. The conclusion from these randomized
studies is that MAC is still the standard regimen for
younger patients. RIC can be a suitable alternative in
patients who are older or those not eligible for MAC.
The new RTC regimens may prove to be as effective but
safer regimens that may ultimately replace MAC and
may even be acceptable in MAC-ineligible patients.
Patients seek consultation regarding their prognosis
not only prior to SCT but also as time elapses after-
wards. Many of the clinical factors predictive of LFS in
the early post-transplant period are no longer predictive
later on as the risk for early events declines. Most events
after MAC occur within the first 2 years [10]. In the
largest study of long-term survival including 10,632
patients reported to the CIBMTR as having been alive
and disease-free at the 2 year time-point, the probability
of remaining alive at the 10-year time-point was 85 %
[12]. Older age and chronic GVHD were the main risk
factors in the entire population, while advanced disease
at SCT was an additional risk factor in patients with
leukemia. Relapse and NRM occurred in 10 and 9 % of
AML patients surviving alive and disease-free 2 years
after SCT. The CIBMTR has also designed an online cal-
culator for estimation of subsequent LFS [25]. However,
these data apply only to MAC, and data regarding the
kinetics of post RIC events are scarce. The current
analysis shows that most events after RIC also occur in
the first 2 years. The 10-year OS of patients alive and
disease-free 2 years after SCT was 73 and 74 % after
Fig. 3 Subsequent outcomes of patients who were leukemia-free 2 years after stem cell transplantation. Relapse incidence (a) and non-relapse
mortality (b)
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MAC and RIC, respectively, with advanced disease at
SCT been the major prognostic factor. These rates are
mildly lower than those reported in the CIBMTR study;
however, in that study, the median age of AML patients
was 28, with only 6 % over age 50 years, while all
patients included in this analysis are over 50 years.
These data can serve to reassure patients given RIC at
the 2 year time-point that their subsequent survival is favor-
able and not significantly different than among those given
MAC. However, the causes of subsequent deaths are some-
what different between RIC and MAC. While relapse is the
major cause of late death in both, it is a more prominent
cause of death after RIC. Chronic GVHD and second can-
cers are more prominent causes of late death after MAC.
Second cancers are the cause of 5–10 % of late mortality
after MAC [11]. Data of the incidence of second cancers
after RIC are limited as extended follow-up is required. In a
single center report from the Tel HaShomer group, the
10-year incidence of second cancers was 1.7 % after MAC,
7.4 % after RIC and 5.7 % after fludarabine-based RTC regi-
mens [26]. After adjusting for patient characteristics, it was
shown that the incidence of second cancers is not reduced
in the RIC/RTC era. A larger CIBMTR study found that
the overall risk of second cancers is reduced after NMA/
RIC although there was an increase of cancers of specific
sites such as head and neck. Among patients aged 40–60
years with MDS and AML, there was no difference between
RIC/NMA and MAC [27]. In the current report, death due
to second cancers was more frequent after MAC. The Tel
HaShomer study speculated that fludarabine may have an
important role in the pathogenesis of second cancers.
Fludarabine-based RTC regimens were included with MAC
in the CIBMTR and current EBMT reports. The current
analysis is only on deaths and among older patients which
may also explain part of these differences. The surveillance
for second cancers remains an important task in long-term
patient education and follow-up [28].
This study has several limitations. This is a retrospect-
ive analysis that compared two not well-matched
cohorts. However, the retrospective design of this study
was the only way to try to answer the question regarding
outcome of patients receiving either RIC or MAC in
clinical practice at the present time. A randomized study
of this size with this long-term follow-up is unlikely to
be performed. While there are differences between the
two groups, especially regarding age at the time of trans-
plantation, the overlap is large enough for a comparison
and allows adjusting for these differences. Other factors
such as source of stem cells and use of in vivo T cell de-
pletion are in part inherent to the conditioning regimen
used and they reflect clinical practice. The objective was
to assess the outcome of the strategies as they have been
used until now including such factors. We focused on
match-sibling donors and therefore the conclusions
cannot be extended to other settings such as SCT from
matched unrelated donors or alternative donors, which
are increasingly been used.
Conclusions
The long-term survival of AML patients age ≥50 years,
given SCT from HLA-matched siblings with RIC or MAC
regimens is similar. The subsequent outcome of 2-year
survivors is also similar as is the kinetics of late events.
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